Contrasting Integra LifeSciences (NASDAQ:IART) and PROCEPT BioRobotics (NASDAQ:PRCT)

Integra LifeSciences (NASDAQ:IART) and PROCEPT BioRobotics (NASDAQ:PRCT) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, institutional ownership, risk, valuation and dividends.

Insider and Institutional Ownership

84.8% of Integra LifeSciences shares are held by institutional investors. Comparatively, 89.5% of PROCEPT BioRobotics shares are held by institutional investors. 3.5% of Integra LifeSciences shares are held by insiders. Comparatively, 17.4% of PROCEPT BioRobotics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Integra LifeSciences and PROCEPT BioRobotics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Integra LifeSciences	-1.78%	12.12%	4.58%
PROCEPT BioRobotics	-36.20%	-28.09%	-20.02%

Analyst Ratings

This is a summary of current recommendations and price targets for Integra LifeSciences and PROCEPT BioRobotics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Integra LifeSciences	4	3	2	0	1.78
PROCEPT BioRobotics	0	1	6	0	2.86

Integra LifeSciences presently has a consensus price target of $18.63, indicating a potential upside of 38.12%. PROCEPT BioRobotics has a consensus price target of $90.00, indicating a potential upside of 52.54%. Given PROCEPT BioRobotics’ stronger consensus rating and higher possible upside, analysts plainly believe PROCEPT BioRobotics is more favorable than Integra LifeSciences.

Risk & Volatility

Integra LifeSciences has a beta of 1.15, suggesting that its stock price is 15% more volatile than the S&P 500. Comparatively, PROCEPT BioRobotics has a beta of 1.07, suggesting that its stock price is 7% more volatile than the S&P 500.

Valuation and Earnings

This table compares Integra LifeSciences and PROCEPT BioRobotics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Integra LifeSciences	$1.61 billion	0.65	-$6.94 million	($0.38)	-35.49
PROCEPT BioRobotics	$224.50 million	14.54	-$91.41 million	($1.70)	-34.71

Integra LifeSciences has higher revenue and earnings than PROCEPT BioRobotics. Integra LifeSciences is trading at a lower price-to-earnings ratio than PROCEPT BioRobotics, indicating that it is currently the more affordable of the two stocks.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services. It also sells instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute wounds; and surgical tissue repair products for hernia, tendon, peripheral nerve repair and protection. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.

About PROCEPT BioRobotics

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). It also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.